The effect of probiotic on uremic toxins and quality of life in chronic hemodialysis patients

The effect of probiotic (Saccharomycesboulardi) on uremic toxins and quality of life in patients with chronic hemodialysis.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170609034406N4

Enrollment

Registered

2020-02-07

Start date

2019-04-03

Completion date

Unknown

Last updated

2020-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hemodialysis patients. Extracorporeal dialysis

Interventions

Intervention group: The treatment group consists of 60 patients receiving Daily Yeast 500 mg produced by Zist takhmir factory, once daily for 4 months.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Begining of hemodialysis from previous 3 months for three times a week Ability to understand and sign a consent form Use of biocompatible dialysis membrane Properly functioning arteriovenous fistula or catheter

Exclusion criteria

Exclusion criteria: Pregnancy and lactation Use of broad-spectrum antibiotics in the last 3 months or now Allergy to probiotics The presence of any chronic, active, uncontrolled or severe chronic inflammatory disease (autoimmune diseases, connective tissue disease, malignancy, HIV, liver disease and pulmonary disease) The presence of chronic or acute infection in a recent month Concurrently presence in another trial (drug or supplement) A history of stroke or myocardial infarction in the last 3 months Receiving medications which are effective on inflammatory factors (corticosteroids or other immunosuppressive drugs, nonsteroidal anti-inflammatory drugs, contraceptives, pentoxifylline)

Design outcomes

Primary

Measure	Time frame
Serum level of Indoxyl Sulphate. Timepoint: Before intervention-At the end of intervention. Method of measurement: ELISA kit.;Serum level of P-cresyl sulphate. Timepoint: Before intervention-At the end of intervention. Method of measurement: ELISA kit.;Serum level of P-cresol. Timepoint: Before intervention-At the end of intervention. Method of measurement: ELISA kit.	—

Secondary

Measure	Time frame
Quality of life. Timepoint: Before intervention-At the end of intervention. Method of measurement: Short form (36) quality of life survey.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfshin Gharekhani

Tabriz University of Medical Sciences

gharekhania@tbzmed.ac.ir+98 41 3335 5921

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026